Sacubitril/Valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: an opportunity to prevent progressive disease | Cardiovascular Diabetology
Neprilysin activity in clinical pre-heart failure Activity of NEP enzyme, the primary target of Sacubitril, was quantified in plasma of a sub-cohort of pre-HFpEF patients with DM from the PARABLE trial [15] (n = 60/250) to understand impact of Sacubitril/Valsartan in this specific population. Type 2 DM patients (n = 44/60) showed positive correlation between plasma NEP activity at … Read more